Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation
- 1 December 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 52 (6) , 1030-1037
Abstract
Treatment with angiotensin II receptor blockers is associated with lower risk for the development of type 2 diabetes mellitus compared with thiazide diuretics. The Mechanisms for the Diabetes Preventing Effect of Candesartan Study addressed insulin action and secretion and body fat distribution after treatment with candesartan, hydrochlorothiazide, and placebo. Twenty-six nondiabetic, abdominally obese, hypertensive patients were included in a multicenter 3-way crossover trial, and 22 completers (by predefined criteria; 10 men and 12 women) were included in the analyses. They underwent 12-week treatment periods with candesartan (C; 16 to 32 mg), hydrochlorothiazide (H; 25 to 50 mg), and placebo (P), respectively, and the treatment order was randomly assigned and double blinded. Intravenous glucose tolerance tests and euglycemic hyperinsulinemic (56 mU/m 2 per minute) clamps were performed. Intrahepatic and intramyocellular and extramyocellular lipid content and subcutaneous and visceral abdominal adipose tissue were measured using proton magnetic resonance spectroscopy and MRI. Insulin sensitivity (M-value) was reduced following H versus C and P (6.07±2.05, 6.63±2.04, and 6.90±2.10 mg/kg of body weight per minute, mean±SD; P ≤0.01). Liver fat content was higher ( P P P <0.05) after H, but not C, versus P. There were no changes in body fat, intramyocellular lipid, extramyocellular lipid, or first-phase insulin secretion. Blood pressure was reduced similarly by C and H versus P. In conclusion, visceral fat redistribution, liver fat accumulation, low-grade inflammation, and aggravated insulin resistance were demonstrated after hydrochlorothiazide but not candesartan treatment. These findings can partly explain the diabetogenic potential of thiazides.Keywords
This publication has 47 references indexed in Scilit:
- Components of Metabolic Syndrome Predicting Diabetes: No Role of Inflammation or DyslipidemiaObesity, 2007
- Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysisThe Lancet, 2007
- Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic SyndromeDiabetes Care, 2006
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Ramipril and the Development of DiabetesJAMA, 2001
- Insulin Resistance and Diabetes in the Context of Treatment of HypertensionBlood Pressure, 1998
- Long-term metabolic effects of antihypertensive drugsAmerican Heart Journal, 1994
- Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular DiseaseDiabetes Care, 1991
- Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus.Hypertension, 1991
- A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with HypertensionNew England Journal of Medicine, 1989